Clinical trial
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203021
Study timeline
Study start (actual)1994-03-26Date precision: day
Registry last updated2020-02-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Relapsing-Remitting Multiple Sclerosisunresolved
Interventions
Glatiramer acetateDRUG · verified · RxNorm: glatiramer acetate
Sponsors & collaborators
Teva Branded Pharmaceutical Products R&D, Inc.lead sponsor
Mapped research locations
Los AngelesCalifornia, United States2HoustonTexas, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1DetroitMichigan, United States1RochesterNew York, United States1New HavenConnecticut, United States1Salt Lake CityUtah, United States1AlbuquerqueNew Mexico, United States1MadisonWisconsin, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00203021 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.